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Crystal structures represent the static picture in the life of a molecule giving a sneak
preview what it might be in reality. Hence, it is very hard to extrapolate from these
photos toward dynamic processes such as transcriptional regulation. Mechanistically VDR
may be considered as molecular machine able to perform ligand-, DNA- and protein
recognition, and interaction in a multi-task manner. Taking this into account the functional
net effect will be the combination of all these processes. The long awaited answer to
explain the differences in physiological effects for various ligands was one of the biggest
disappointment that crystal structures provided since no substantial distinction could be
made for the conformation of the active VDR-ligand complexes. This may have come
from the limitation on the complexity of the available ligand-VDR structures. The recent
studies with full length VDR-RXRα showed somewhat more comprehensive perspective
for the 3D organization and possible function of the VDR-RXRα-cofactor complex. In
addition to in vitro approaches, also computational tools had been introduced with the
aim to get understanding on the mechanic and dynamic properties of the VDR complexes
with some success. Using these methods and based on measurable descriptors such as
pocket size and positions of side chains it is possible to note subtle differences between
the structures. The meaning of these differences has not been fully understood yet but
the possibility of a “butterfly effect” may have more extreme consequences in terms
of VDR signaling. In this review, the three functional aspects (ligand-, DNA- and protein
recognition, and binding) will be discussed with respect to available data as well as
possible implication and questions that may be important to address in the future.
Keywords: VDR, crystal structure, molecular dynamics, molecular mechanism, cofactors, response elements,
ligand-binding
INTRODUCTION
One way of understanding life at molecular level is to obtain the
three-dimensional (3D) structures of the molecules. Such struc-
tural views represent a static picture in the life of amolecule giving
a sneak preview what it might be in reality. For the understanding
of the functional implication of vitaminD (VD) signaling it is also
important to look at various structural complexes of the vitamin
D receptor (VDR), which may outline its possible dynamics and
mechanics. VDR is able to perform the ligand-, DNA- and protein
recognition, and interaction in a multi-task manner thus can be
viewed as molecular machine which will regulate gene expression
with the combination/sum of all these particular functions.
Before the year 2000 people in the VD field were only guessing
how may the 3D structure of VDR look like. Some implications
Abbreviations: 1,25D3, 1α, 25-dihydroxyvitamin D3; 3D, three-dimensional;
3Klca, 3-keto lithocholic acid; 9-cis RA, 9-cis retinoic acid; aa, amino acids; cryo-
EM, cryo-electron microscope; Cyp27b1, 25-hydroxyvitamin D3 1α-hydroxylase;
D.rerio, Danio rerio; DBD, DNA-binding domain; DNA, deoxyribonucleic acid;
DR, direct repeat; DRIP, vitamin-D-receptor interacting protein; h, human; H.
sapiens, Homo sapiens; HDX, H/D exchange; LBD, ligand-binding domain; LBP,
ligand-binding pocket; LCA, lithocholic acid; MD, molecular dynamics; OH,
hydroxyl; P. marinus, Petromyzon marinus; PXR, pregnane X recptor; RAR,
Retinoic acid receptor; r, rat; R. norvegicus, Rattus norvegicus; RE, response element;
RID, receptor interaction domain; RXR, retinoid X receptor; SAXS, short angle X-
ray scattering; TR, thyroid hormone receptor; VD, vitamin D; VDR, vitamin D
receptor; VDRE, VD response element; z, zebrafish.
were coming from already known crystal structures e.g., recep-
tors for retinoids such as retinoid X receptor (RXR) (Bourguet
et al., 1995) and retinoic acid receptor (RAR) (Renaud et al.,
1995). Not until exactly 14 years ago the structure of VDR-1α,25-
dihydroxyvitamin D3 (1,25D3) complex has been solved (Rochel
et al., 2000) and a long journey started in understanding the
binding of various VDR analogs and the structure-based analog
design. Within the first 5 years more structures have been solved
(Tocchini-Valentini et al., 2001, 2004; Eelen et al., 2005) but the
long awaited answer to explain the differences in physiological
effects for various ligands was one of the biggest disappointment
that crystal structures provided since no substantial distinction
could be made for the conformation of the active VDR-ligand
complexes.
Compared to the beginning of the last decade a huge number
of X-ray crystal structures are available for VDR. In detail, there
are VDR LBDs from three different species H. sapiens (34), R.
norvegicus (40) and D. rerio (13) and four DBD-DNA complexes
from H. sapiens. The basic information about these complexes is
summarized in Table 1. This data makes also possible to analyze
orthologous molecules with reflection to functional and struc-
tural differences. However, to understand this aspect well it would
be beneficial to have more data from numerous organisms. In
this review evolutionary aspects and species-specific difference
will be not discussed in depth. More space will be given to
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general domain organization, binding mode of natural ligands
and recognition of DNA by VDR. Some data coming frommolec-
ular dynamics (MD) simulations will be also discussed since this
approach represents a compromise in obtaining 3D structural
models and have been proven to be well aligned with the wet
lab data. At last, recent data from small-angle X-ray scattering
(SAXS), cryo-electron microscopy (cryo-EM) and H/D exchange
(HDX) experiments will be discussed with some perspectives
highlighted.
WHAT DO VDR STRUCTURES TELL US?
From functional and structural organization point of view VDR
is formed by DNA-binding domain (DBD:24–89 aa; domain C),
ligand-binding domain (LBD:126–427 aa; domain E), a connec-
tive hinge (domain D) between them and a short A/B domain
located at the N-terminus. Compare to RXR it completely lacks
the F domain, which is the very last part of the LBD after helix 12.
The LBD is formed by a three layer anti-parallel α-helical sand-
wich (Figures 1A,B highlighted in green, blue and red). Based of
the particular structure it contains all together 11–13 α-helices
(Li et al., 2003) (Figure 2A). The internal structure of the LBDs
of the respective nuclear receptors (NRs) shows a high simi-
larity with specialized diversity based on functional properties
of the particular receptor. In VDR, the LBD is responsible for
active ligand recognition and interaction with partnering proteins
such as coregulators, and RXR to form the functionally active
RXR-VDR heterodimer. In particular, helices 3, 4, and 10–12 are
involve in the interaction with protein partners. Interestingly, to
date all solved VDR crystal structures show very ubiquitous and
conserved organization of the of overall structural fold not reflect-
ing the divergent nature of the bound natural or synthetic ligands.
What are in fact the differences in structures that reflect various
physiological effects of the particular ligands? Allegedly there will
not be a simple answer to this question since we may face the
limitation on the complexity of the available ligand-VDR struc-
tures or have to allow the possibility that the subtle differences
between the structures may cause a “butterfly effect” that have
more extreme consequences in terms of VDR signaling than ini-
tially thought. By all means there are important differences in the
metabolism of various synthetic ligands and a possible unique
coactivator recruitment may also play its role. However, none of
these possibilities can be fully explored using the available VDR
crystal structures. Nevertheless, what we may agree on is that
all VDR crystal structures show agonistic conformation, surpris-
ingly even in case of antagonists, that is canonically represented
by a closed conformation of the helix 12 providing a docking
platform for the recruitment of coactivators. This may be due to
the shifted equilibrium that drives VDR for closed helix 12 with
minimal energy conformation. In addition, the VDR structures
do tell us the binding mode, anchoring points and subtle changes
FIGURE 1 | VDR shows similarity to canonical NR structural
organization. (A) The overall surface depiction of the VDR showing
the three layers sandwich-like molecule where the layers are
highlighted in green, blue and red. (B) Numbered helices belonging to
different layers are shown and they are highlighted similarly as in
surface representation.
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FIGURE 2 | General view of the VDR. (A) Ribbon representation of the
VDR with annotated helices. The very last helix (helix 12) is highlighted
in red color. (B) The binding mode of the 1,25D in the ligand-binding
pocket (LBP). The important anchoring residues and their location in the
VDR structure is depicted. Hydrogen bonds are shown in blue (for details
see the text).
in the position of residues that may be effectively used for de
novo design of superagonist such as AMCR277A (PDBID:3CS4)
(Hourai et al., 2008). The frequently mentioned subtle changes
that are characteristic for the ligand-binding pocket (LBP) may
be further analyzed and can explain some of the binding differ-
ences between various ligands in correlation to their functional
and biological properties.
THE INNER CIRCLE: LOOKING INTO THE VDR POCKETS
The “lower part” of the LBDs of all ligand-activated NRs con-
tains a LBP which volume size range between 400 and 1400Å3
(Figures 2A,B light-brown mesh) (Nagy and Schwabe, 2004). It
is not quite different in case of VDR where LBP primarily serves
for effective recognition of various natural ligands such as 1,25D3
and its metabolites or bile acids. In addition, this is one of the
most important parts to modulate VDR’s activity via various syn-
thetic compounds. The VDR pocket can be placed in the middle
range of the volume scale showing rather high dynamic plasticity
toward various ligands.
The first VDR crystal structure confirmed the conserved con-
tact or anchoring points for the interaction of VDR with 1,25D3
(Rochel et al., 2000) (Figure 2B). The residues involved in the
positioning of the 1,25D3 in the LBP are Y143 (helix 1) and S278
(helix 5) that contact the 1,25D31α-hydroxyl (OH) group, S237
(helix 3) and R274 (helix 5) contact 3β-OH, and H305 (loop 6–7)
and H397 (helix 11) interact with 25-OH. In most of the cases if
these anchoring point are disrupted a decrease in the activation
potential of the ligand can be observed. Besides these residues the
interior surface of the VDR LBP is formed of about 40 mostly
non-polar amino acids. An interesting approach is to look how
the LBP is changed upon ligand-binding especially its volume
or how much volume (%) is occupied by the ligand. A rather
straightforward example is the comparison of the 1,25D3 and
MC1288 LBPs. Although the volumes of these ligands are highly
comparable 434Å3 and 427Å3 (probe radius 1.9 Å), respectively,
the volumes of the LBP show slight differences 776Å3 and 643Å3
(same probe radius) leading to ratio of 56 and 66% of ligand
occupancy of the LBP volume (Molnár et al., 2006). When a lig-
and occupancy is higher compared to 1,25D3 then it increases
the stability of VDR. This factor holds true for ligands that show
high structural similarity and binding mode to 1,25D3. It seems
to some extend that the ratio of the ligand to LBP volume can be
a good descriptor of the ligands’ activation potential. In addition,
the actual shape of the cavity also reflects differences in the bind-
ing of various ligands which is illustrated in Figure 3. There are
slight differences in the shapes of the LBP depending on the
bound ligand. The red arrow shows the part where the shape is
conserved well. Topologically this is the place where the 1,25D3
A-ring is located e.g., helices 1, 3, and 5. The more plastic part is
the one where the 1,25D3 side chain is found with helices 6, 7, and
11. This region shows the highest variation between the ligand-
bound structures and is indicated with green arrow Figure 3. In
addition, small changes can be also detected for instance the part
highlighted with green circle. Very interesting in the difference
between the two Gemini structures 2HCD and 4IA1, where the
largest difference for the two side chains is that “C17–20 threo
20S—Gemini” has the hydrogens in its methyl groups substituted
with deuterium. Interestingly, in this case the pocket shows more
compact shape in the region with the double side chains and the
volume of the location highlighted with green circle is decreased,
whichmay be due tomodification of the A-ring. Another interest-
ing question is the maximum volume to which the VDR LBP can
be stretched. MD simulations showed that by docking a Gemini
with fluorinated methyls groups, (CF3)2-Gemini, the LBP could
www.frontiersin.org June 2014 | Volume 5 | Article 191 | 9
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FIGURE 3 | Shapes of the zebrafish VDR ligand-binding pockets (LBPs) with various compounds (source PDBID: 2HC4, 2HCD, 3DR1, 4G1Y, and 4IA1).
be expanded by 1/3 of the 1,25D3 LBP volume. In proportion
to this, the compound’s volume in the pocket is also increased
about 30%.
An appealing view opens up when a comparison of the VDR
structure with one of its closest relative pregnane X receptor
(PXR) is made (Watkins et al., 2001). As for VDR there are plenty
of PXR crystal structures available and it can extend its LBP
to very large volume (∼1400Å3) to accommodate various com-
pounds. The published VDR structures lack the insertion domain
(166–216 aa), but even without it the LBP as discussed earlier is
as large as 700–800Å3 with MD simulations showing that it can
expand beyond 1000Å3, which is already comparable to PXR’s
LBP. This may suggest that VDR is able to accommodate variety
of other compounds in addition to 1,25D3 such as LCA/3-keto-
LCA (Makishima et al., 2002). The later have been crystallized
with rVDR and will be discussed in this review. The indications
for binding additional compounds besides 1,25D3 are coming
also from P. marinus (sea lamprey) where despite of lack of the
calcified skeleton and teeth it may serve as a xenobiotic activator
for detoxification by regulating P450 enzymes (Whitfield et al.,
2003; Krasowski et al., 2005). However, it is yet to be determined
whether there are existing other ligands that bind to VDR. One
part of the LBD, whichmay allow the binding of these compounds
is the insertion domain. Although its clear functional role has not
been identified and it seems that it is not directly required for
the binding of the 1,25D3 (Rochel et al., 2001), it may play some
other roles. A mutation C190W was reported in patients that
results in loss of 1,25D3 binding (Malloy et al., 1999), though this
may be due to the disruption of the VDR structure by introduc-
ing a large bulky tryptophan residue. Secondly, the homologous
part of PXR (142–431 aa) especially the occurrence of the two β-
strands and the associated coiled regions are responsible for the
expandability of the PXR’s LBP thus an analogous role cannot
be out ruled in case of VDR as well. There has been also pro-
posed that an alternative pocket, which can be considered as an
enlargement of the original pocket, is formed in the VDR that
Frontiers in Physiology | Integrative Physiology June 2014 | Volume 5 | Article 191 | 10
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extends toward the helix 2/β-sheet region of the LBD (Mizwicki
et al., 2004). Especially this can be observed with covalently locked
1,25D3-derived compounds such as 1,25(OH)2-lumisterol, which
has been showed by in silico docking studies.
Due to the space limitation this review cannot address and
discuss all the VDR-ligand complexes, for some more details
see text below or recent reviews (Carlberg and Molnár, 2012;
Carlberg et al., 2012), but some of the structures with nat-
ural ligands will be discussed in more details. One of them
is 3-epi-1α,25-dihydroxyvitamin D3 (3-epi-1,25D3) a 1,25D3
metabolite that has been shown to exhibit tissue specific activities
comparable to 1,25D3 (Norman et al., 1993; Reddy et al., 2000).
The structural analysis showed a binding mode very similar to
that of 1,25D3 with interesting compensation for the lacking
S278-3α-OH hydrogen bond for the epimer using water mediated
contacts Figure 4 (Molnár et al., 2011). Interestingly, the same
water channel is present in the 1,25D3 complex and was observed
with other complexes as well (Tocchini-Valentini et al., 2001;
Hourai et al., 2006).
A widely accepted fact is that precursor 25-hydroxyvitamin D3
(25D3) and its metabolite 24R,25-hydroxyvitamin D3 (24,25D3)
does not posses significant biological activities. However, it has
been shown that in Cyp27b1−/− cells, that are unable to pro-
duce actively 1,25D3, the VD signaling may be primary mediated
via 25D3 (Lou et al., 2010). It stays a matter of discussion that
under physiological condition how much of the VD signaling is
mediated via 1,25D3 vs. 25D3. 24,25D3 shows only weak potency
of influencing VD signaling at concentration 500nM although
an enhancement for human osteoblast differentiation has been
shown at concentration 1μM (van Driel et al., 2006). Docking
and subsequent MD simulations have been done to see the
FIGURE 4 | Binding mode of 1α, 25-dihydroxyvitamin D3 and
3-epi-1α,25-dihydroxyvitamin D3 in the LBP of human VDR (source
PDBID: 1DB1 and 3A78). 1,25D3 and 3-epi-1,25D3 are highlighted in green
and blue color, respectively. The hydrogen bonds are in green and blue
dashed lines.
binding mode of these compounds and it has been confirmed
that the position of residues mediating the anchoring hydrogen
bonds are conserved with the exception of R274 which is located
further than 3.5 Å from 24,25D3 Figure 5. Another residue that
is unable to make a binding contribution is S237, but its posi-
tion in the pocket is maintained. The void created by the missing
R274 increases the LBP and lowers the occupancy factor for this
compound. The analysis of the simple binding mode confers the
activity range from 1,25D3 > 25D3 > 24,25D3. This also shows
in general the importance of the 1α-OH group for the potency of
the VDR agonist.
Recently, the crystal structures for another group of natural
ligands have been solved. From the identification of secondary
bile acids as VDR agonist (Makishima et al., 2002) the interest-
ing question remained how these compounds bind to VDR. From
the structural data it is evident that the litocholic acid (LCA)
and 3-keto litocholic acid (3kLCA) are located in the opposite
orientation than 1,25D3 (Figure 6). The 24-carboxyl group faces
the β-turns of VDR, the β-region of the steroid backbone the
helix 6–7/11 region and the A-ring is in the direction of helix 12.
The S274 (hVDR S278) and Y143 hydrogen bonds are conserved
FIGURE 5 | Binding mode of 1α, 25-dihydroxyvitamin D3,
25-hydroxyvitamin D3 and its metabolite 24R,25-hydroxyvitamin D3 in
the LBP of human VDR (source MD simulation Lou et al., 2010). 1,25D3
and 25D3/24,25D3 and are highlighted in green and blue color, respectively.
The hydrogen bonds are in green and blue dashed lines.
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FIGURE 6 | Binding mode of 1α, 25-dihydroxyvitamin D3, lithocholic acid and 3-ketolitocholic acid in the LBP of rat VDR (source PDBID: 1RK3, 3W5P,
and 3W5Q). 1,25D3 and LCA/3kLCA and are highlighted in green and blue color, respectively. The hydrogen bonds are in green and blue dashed lines.
in all structures (Figure 6). The difference for this part of the
ligand-binding comes from the water mediated contacts with
both R270 (hVDR R274) and S233 (hVDR S237). These con-
tacts seem to be weaker compare to 1,25D3 but not so weak as
in case of 25D3 and 24,25D3, where in fact they are missing due
to lack of 1α-OH group. The opposite part of the bile acids shows
also weaker hydrogen bonding network than for the previously
discussed VD metabolites including 1,25D3. The structural com-
parison between the two bile acids shows a less complex, more
straightforward binding mode for 3kLCA with only one water
molecule involved. Whereas, for LCA there are no direct con-
tacts with H301 (hVDRH305) and H393 (hVDRH397). All these
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contacts are mediated thorough waters. This also may explain the
lower VDR activation potential of 3kLCA compared to LCA.
I would seems that the evolutionary design of VDR reached by
recognizing 1,25D3 its perfection. All the anchoring points show
effective hydrogen bonding and by looking at the limited data for
natural ligands any deviation from 1,25D3 will result in the use
of alternative bridging contacts such water molecules. This shows
a rather limited adaptability of VDR in effectively recognizing its
natural ligands, yet larger than we envisioned a decade ago. One
must keep inmind that the activation of VDRwith one or another
metabolite will largely depend on the local cellular concentration
of this compounds leading for instance for favored activation via
bile acids instead of classical 1,25D3 binding.
DNA-RECOGNITION AND BINDING
VDR belongs to the class of zinc finger transcriptional factors
with DBD that consists of a highly conserved 66 aa residue
core (Khorasanizadeh and Rastinejad, 2001) and an adjacent C-
terminal extension. The conserved core has two zinc fingers where
one contains fours cystein residues per atom of zinc (Figure 7).
This feature allows VDR to effectively recognize and bind hor-
mone response elements (REs) - termed VDREs. VDREs are
FIGURE 7 | The overall architecture of the DBD complex of RXR-VDR
on canonical DR3 element (PDBID: 1YNW). The two zinc atoms (light
blue spheres) with the respective cysteins are shown (bottom). RXR is
shown in blue and VDR in green. The coiled protein regions are in
gray and β-sheets in yellow. The surface representation of the contact
atoms interacting between DNA and the heterodimer is shown (top).
The proteins and DNA are visualized in different color DNA (red), RXR
(blue), and VDR (green).
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typically made up of two hexameric half-sites whose consen-
sus sequence is 5′-RGKTCA-3′, where R = A or G and K =
G or T. The half-sites may be arranged in various orientation
most commonly forming a direct repeat with three neutral base
pairs separating the half-sites (DR3) (Umesono et al., 1991).
The unliganded VDR can occupy its REs also as a homodimer
(Carlberg et al., 1993). Upon binding of ligand, VDR interacts
with RXR and forms a heterodimeric complex that binds to
VDREs with 5′-prime bound RXR.
The data for structural view on VDR-DNA recognition is
scarce. To date we have only four structures published where
three represent VDR homodimers on direct repeat 3 (DR3) from
mouse osteopontin (mSPP) (CACGGTTCACGAGGTTCA), rat
osteocalcin promoter (rOC)(CACGGGTGAATGAGGACA) and a
canonical DR3 element (cDR3) (CACAGGTCACGAAGGTCA)
(Table 1) (Shaffer and Gewirth, 2002). The last structure
represents the DBDs of the heterodimeric RXR-VDR on canonical
DR3 element (cDR3) (TTAGGTCACGAAGGTCAA) (Table 1)
(Shaffer and Gewirth, 2004). The 66 to 70 aa of the DBD are
structurally coordinated by two zinc atoms that create a structure
(Figure 7), in which one short α-helix is interacting directly with
the major groove of the DNA (Härd et al., 1990; Lee et al., 1993).
The VDR homodimers show asymmetric head to tail arrange-
ments. The experimentally determined range of affinities of DR3s
used for crystallographic studies are mSPP > cDR3 > rOC with
mSPP supporting both VDR homodimer and RXR-VDR het-
erodimer binding, cDR3 requiring 10x higher VDR homodimer
protein levels and weak heterodimer binding, whereas rOC is
unable to bind VDR homodimers and has a very weak het-
erodimer binding ability (Freedman and Towers, 1991; Nishikawa
et al., 1993; Toell et al., 2000). The change at third position, a
purine to pyrimidine, of the consensus half sites AGGTCA allows
the additional water mediated hydrogen contact of E42 with
the DNA, which increase the stability of the mSPP-VDR com-
plex. In case of rOC the reason for diminished VDR homodimer
binding is because there is a G at position five of the upstream
half-site GGGTGA, where supposedly RXR is bound in case of
heterodimer binding. In high affinity half-sites in this location
there is a C in the first strand but a complementary G in the sec-
ondDNA strand. The interaction, which involves hydrogen bonds
is between the R50 of VDR and the G from the second comple-
mentary strand. In rOC upstream half-site instead of G there is
a C in the second strand, which is not a hydrogen bond acceptor
thus R50 cannot interact with it. There is also some agreement
between the strength of the homodimer binding and a sum of
all existing DNA-VDR contacts within 3.5 Å calculated with the
ncont program of the CCP4 suite (Winn et al., 2011). The results
show 88, 85, and 83 contacts for rOC, cDR3, and mSPP, respec-
tively. Interesting is also the interacting surface ratio between
the two VDR homodimer molecules in percentage (5′upstream:
3′downstream) 38.52:61.48% for rOC, 46.21: 53.8% for the cDR3
and a reversed ratio of 57.3:42.7% for mSPP. This would sug-
gest that for strong VDR homodimer binding there is a more
contribution from the upstream half-site, but a clear conclusion
cannot be reached based on this limited data set. In the RXR-
VDR crystal structure there are two asymmetric units where the
full complex shows an orientation RXR to VDR for unit 2 and
a reversed orientation VDR to RXR for unit 1 with RXR bound
on the downstream part of the VDRE. This may be due to the
stabilization contacts between the adjacent VDRmolecules where
the hinge of one VDR molecule is stabilized with the DBD of the
second VDR molecule. The general organization of the unit 2 is
depicted also on the Figure 7 bottom. The two zinc atoms (light
blue color) with the respective cysteins are visualized (the second
heterodimer unit is missing from the representation). The over-
all number of contacts is only 65, which is much lower than in
case of VDR homodimers discussed earlier. This indicates that the
binding of the RXR-DBD heterodimer to cDR3s is not optimal
and for an effective binding a certain point of VDRE degener-
ation is needed. Moreover, the contribution of the monomers
to the binding is rather interesting. The ratio between interact-
ing monomeric surfaces is 56.22:44.26% (RXR-VDR) suggesting
a higher contribution of RXR to the binding Figure 7 top (see
also theH/D exchange experiments discussed below). This is most
likely due to the reverse orientation of the RXR-VDR on the
cDR3. The surfaces of the interacting atoms are visualized in dif-
ferent color DNA (red), RXR (blue) and VDR (green). It is to be
noted that compared to DNA-protein interaction there are hardly
any interactions between the protein monomers. None for RXR-
VDR, for VDR homodimers there are two formSPP and rOC, and
five on cDR3. This is quite in agreement with full length recep-
tor studies which suggest that most of the heterodimerisation is
contributed from hinges and LBDs.
THE OUTSIDE SHELL: PARTNERING AND THE COMPLEX
VIEW
VDR INTERACTING PROTEIN PARTNERS
For VDR to function effectively as a regulator of transcription it
is inevitable to interact with various protein partners. They show
high structural and functional diversities ranging from enzymes,
co-integrators and cofactors to components of distinct transduc-
tion signaling pathways. A comprehensive list of these partners
with the accompanying citations are listed in Table 2.
One of the first complex identified using co-immuno-
precipitation from mammalian cells was the VDR interacting
protein DRIP complex, which is recruited to VDR in a completely
ligand-dependent manner (Rachez et al., 1999). Many of the its
components were shared with the earlier identified thyroid hor-
mone receptor (TR) interacting protein complex TRAP (Fondell
et al., 1996). It has been no surprise that majority of the interact-
ing proteins can be related directly to transcriptional regulation
such as subunits of the mediator complex MED1, 4, 6, 7, 12, 16,
17, and 23 (Rachez et al., 1999) or cofactors such as coactivators
NCOA1-3 (Hong et al., 1997; Castillo et al., 1999; Molnár et al.,
2005), NCOA6 (Mahajan and Samuels, 2000), ARA54 (Ting et al.,
2005), SKIP (Baudino et al., 1998), RBP2 (Chan andHong, 2001),
SRB7 (Ito et al., 1999) and corepressors Alien (Polly et al., 2000),
NCOR1 and 2 (Tagami et al., 1998; Kim et al., 2009), SIN3A
(Fujiki et al., 2005), LCOR (Fernandes et al., 2003). Others show
more selective properties functioning as coactivators and core-
pressors depending on the particular conditions such as RIP140
(Albers et al., 2005) or TIF1α (Thénot et al., 1997). Some are
implicated in cellular processes such as cell cycle regulation CDK7
(Nevado et al., 2004), RAP46 (Guzey et al., 2000), DNA repair
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Table 2 | List of VDR interacting proteins.
Name Gene symbol/alternative name Role References
Alien ALIEN Transcriptional corepressor Polly et al., 2000
Androgen receptor-associated protein 54 ARA54* Transcriptional coactivator Ting et al., 2005
Androgen receptor-associated protein 70 ARA70 Transcriptional coactivator
implicated in cancer
Ting et al., 2005
Brahma-related gene 1 BRG1/SMARCA4 ATPase subunit of the SWI/SNF
complex
Fujiki et al., 2005
CREB-binding protein CBP Transcriptional cointegrator Castillo et al., 1999
Cyclin D3 CCD3 Subunits of the cyclin-dependent
kinases
Jian et al., 2005
Cyclin-dependent kinase 7 CDK7/hMo15 Component of the TFIIH
transcription complex
Nevado et al., 2004
CXXC finger 5 CXXC5 Cell cycle regulation Marshall et al., 2012
E1A binding protein p300 p300 Transcriptional cointegrator Kim et al., 2005
Fas-activated serine/threonine kinase FASTK Involvement in splicing Marshall et al., 2012
Feline Gardner-Rasheed sarcoma viral
oncogene homolog
FRG Signal transduction (protein
tyrosine kinase)
Ellison et al., 2005
General transcription factor IIB TFIIB Subunit of the basal transcription
machinery
Nevado et al., 2004
Hairless HR Transcriptional corepressor Hsieh et al., 2003
High mobility group nucleosomal binding
domain 3
HMGN3/TRIP7 Possible chromatin modifier Albers et al., 2005
Histone deacetylase 2 HDAC2 Histone modifier Fujiki et al., 2005
Ligand-dependent NR corepressor LCOR Transcriptional corepressor Fernandes et al., 2003
Mediator complex subunit 1 MED1/TRAP220/RIP205/PPARBP Transcriptional regulation/part of
the mediator
Rachez et al., 1999
Mediator complex subunit 4 MED4/DRIP36/p34 Transcriptional regulation/part of
the mediator
Rachez et al., 1999
Mediator complex subunit 6 MED6/DRIP33 Transcriptional regulation/part of
the mediator
Rachez et al., 1999
Mediator complex subunit 7 MED7/DRIP34 Transcriptional regulation/part of
the mediator
Rachez et al., 1999
Mediator complex subunit 12 MED12/DRIP240/ARC240/TRAP230 Transcriptional regulation/part of
the mediator
Rachez et al., 1999
Mediator complex subunit 16 MED16/DRIP92/TRAP95 Transcriptional regulation/part of
the mediator
Rachez et al., 1999
Mediator complex subunit 17 MED16/DRIP77/TRAP80 Transcriptional regulation/part of
the mediator
Rachez et al., 1999
Mediator complex subunit 23 MED23/DRIP130/CRSP130 Transcriptional regulation/part of
the mediator
Rachez et al., 1999
Mothers against decapentaplegic
homolog 3
SMAD3 Transcriptional coactivator Yanagisawa et al., 1999
Myosin light chain 3 MYL3 Regulatory light chain of myosin Marshall et al., 2012
NR coactivator 1 NCOA1/SRC1 p160 family coactivator Castillo et al., 1999
NR coactivator 2 NCOA2/TIF2/GRIP1 p160 family coactivator Hong et al., 1997)
NR coactivator 3 NCOA3/RAC3/SRC3/AIB1 p160 family coactivator Molnár et al., 2005
NR coactivator 6 NCOA6/PRIP/ASC2 Transcriptional coactivator Mahajan and Samuels,
2000
NR corepressor 1 NCOR1 Transcriptional corepressor Tagami et al., 1998
NR corepressor 2 NCOR2/SMRT/TRAC2 Transcriptional corepressor Kim et al., 2009
NR subfamily 0, group B, member 2 NR0B2 (SHP) Negative transcriptional regulator Albers et al., 2005
NR subfamily 4, group A, member 1 NR4A1 (NGFIB) Expression genes during liver
regeneration
Marshall et al., 2012
p53 PT53 Tumor supression Stambolsky et al., 2010
(Continued)
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Table 2 | Continued
Name Gene symbol/alternative name Role References
Receptor-associated protein 46 RAP46/BAG1 Regulation of cell growth in
response to stress
Guzey et al., 2000
Receptor-interacting protein 140 RIP140/NRIP1 Coregulator with selective
properties
Albers et al., 2005
Retinoblastoma 1 RB NR coregulator/tumor suppressor Chan and Hong, 2001
Retinoblastoma-binding protein 2 RBP2 Transcriptional coactivator Chan and Hong, 2001
Retinoid X receptor α RXRα Heterodimeric VDR partner Liu et al., 2000
Retinoid X receptor β RXRβ Heterodimeric VDR partner Rachez et al., 1999
Retinoid X receptor γ RXRγ Heterodimeric VDR partner Albers et al., 2005
Protooncogene c jun JUN Transcriptional factor Towers et al., 1999
SIN3 homolog A, transcriptional
regulator (yeast)
SIN3A Transcriptional
corepressor/cointergrator
Fujiki et al., 2005
SKI interacting protein SKIP/SNW1/NCoA-62 Transcriptional coactivator Baudino et al., 1998
Suppressor of RNA polymerase B 7 SRB7 Transcriptional coactivator Ito et al., 1999
Thymine-DNA glycosylase TDG Coregulator/base excision repair Chen et al., 2003
Thyroid receptor-interacting protein 1 TRIP1/SUG1/PSMC5 CAD (Conserved ATPase domain)
protein
Masuyama and
Hiramatsu, 2004
Transcriptional intermediary factor 1 TIF1α/CCCP Coregulator with selective
properties
Thénot et al., 1997
Tropomyosin TPM2 Possible role in receptor
Internalization
Marshall et al., 2012
Vitamin D receptor-interacting protein
(100kD)
DRIP100/ARC100/TRAP100 VDR associated DRIP complex Rachez et al., 1999
Vitamin D receptor-interacting protein
(150kD)
DRIP150/ARC150/TRAP170 VDR associated DRIP complex Rachez et al., 1999
Vitamin D receptor-interacting repressor VDIR/TCF3/ITF1 Negative regulator of the
CYP27B1
Kim et al., 2007
Williams syndrome transcription factor WSTF/BAZ1B Recruitment of unliganded VDR
to target promoters
Fujiki et al., 2005
Xin actin-binding repeat containing
protein 1
XIRP1 Protects actin filaments from
depolymerization
Marshall et al., 2012
*no direct physical interaction but has positive effect on VDR transactivation.
TDG (Chen et al., 2003) or signaling cascade FRG (Ellison et al.,
2005). Interesting is the interaction and thus possible crosstalk
with other NRs such as SHP (Albers et al., 2005), which lacks
DBD and has corepressor-like behavior, and NGFIB, which has
been shown to have a role during liver regeneration (Marshall
et al., 2012). Some of the newly identified protein partners that
may implicate VDR’s involvements in new processes are XIRP1
that protects actin filaments from depolymerization or MYL3 a
regulatory light chain of myosin (Marshall et al., 2012).
STRUCTURAL DATA OF SRC1 AND MED1/DRIP205 INTERACTION
WITH VDR
There is a big limitation in obtaining large transcriptional com-
plexes, which is firstly due to the transient nature of the complex
where VDR serves as a docking and acquiring platform bring-
ing other proteins that either act as chromatin modifiers, parts
of the mediator, of various cofactors and bridging factors to the
close proximity of the functional VDREs. The complex may be
assembled for a short moment to initiate and/or repress the tran-
scription thereafter fulfilling this action it falls apart. The second
reason might be that many of the interacting proteins such as
cofactors show a high degree of disorder. The crystallization of
unfolded proteins is very tricky and many times even impossi-
ble. The intrinsic disorder of a VDR interacting proteins is an
expected structural property since e.g., members of the p160 gen-
eral coactivator family have to adopt and interact with many
various transcription factors. Thus structural data from only
short interacting peptides derived from steroid receptor coacti-
vator 1 (SRC1) with zVDR (Figure 8A) and mediator complex
subunit 1 (MED1/DRIP205) with rVDR are available showing
only the core interaction between VDR and the LXXLL motif of
coactivators (Figure 8B). Both peptides interact in a very similar
fashion. The α-helix of the peptide is oriented with its N-terminus
toward helix 12. The two peptides interact through their LXXLL
motifs, LHRLL in SRC1 and LMNLL in MED1, and most of the
interaction is contributed from hydrophobic contacts of coac-
tivator’s leucine residues with the hydrophobic core from VDR
helices 3, 4, and 12. The anchoring points of the short α-helix
are based on the interaction with the “charge clamp” consisting
of the conserved glutamate in helix 12 and lysine in helix 3, and
the backbone amides of the coactivator peptide. The similar inter-
action of the two LXXLL motifs raises the question on how the
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FIGURE 8 | The interaction of coactivator peptides with VDR. Peptides
derived from (A) steroid receptor coactivator 1 (SRC1) with zVDR and (B)
mediator complex subunit 1 (MED1/DRIP205) with rVDR shown. SRC1 and
MED1 is shown in orange and VDR in green. Helix 12 is highlighted in red.
The hydrogen bonds and hydrophobic interactions are visualized with green
and gray dashed lines, respectively. The important residues such as the
conserved “charge clamp” glutamate from helix 12 and lysine in helix 3
contributing to the CoA-VDR interaction are also shown.
specificity is achieved in the interaction. The situation is compli-
cated with the fact that some of the coactivators have more than
one interaction motif such as SRC1 has five of them that are simi-
lar or related to LXXLL motifs, but so far only three of them were
reported/studied in detail.
SAXS, CRYO-EM, AND H/D EXCHANGE STUDIES WITH FULL LENGTH
RXR-VDR COMPLEXES
The recent studies with VDR complexes in solution that employed
the use of modern techniques such as SAXS, cryo-EM, HDX with
full length VDR-RXRα showed somewhat more comprehensive
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perspective for the 3D organization and possible function of the
VDR-RXRα-cofactor complex. The SAXS (Rochel et al., 2011)
and cryo-EM (Orlov et al., 2012) derived model is shown in
Figure 9A.
Upon binding to DNA from osteocalcin VDRE, the SAXS
data derived RXR-VDR shows an elongated asymmetric open
conformation with separate DBDs and LBDs and a well
structured VDR hinge with VDR located downstream and RXR
on upstream half sites (Rochel et al., 2011) (Figure 9B). On con-
trary the coiled structure of the RXR hinge allows its adaptability
to different REs. The hinges play an important role in an open
conformation. The hinges also underly one of the very impor-
tant feature of the RXR-VDR complex, the dynamic character.
The DBD binding to DR3 results in a rotation of the LBD dimers
take around 90◦ with respect to the DNA (Figure 9A). The same
study showed that coactivators MED1/DRIP205 and SRC1 have
higher affinity to VDR compared to RXR. This points to the bind-
ing of only one molecule of coactivator through VDR, which is
not supporting the “deck model” of binding (one LXXLL motif
to VDR and the other to RXR) for these coactivators. Studies
usingmutants show the preferential binding of VDR to the second
LXXLL motif of MED1/DRIP205 compared the weak recruit-
ment of the first motif to RXR (Ren et al., 2000). However, both
motifs are crucial for the effectivity of the NR activation complex
in vivo (Malik et al., 2004). RXR may play a role in coactivator
recruitment as well by associating to some other factors.
The cryo-EM studies of the RXR-VDR have a higher resolution
than SAXS data and it is possible to obtain more precise elec-
tron densities for VDR A/B and hinge domains for both receptors
(Orlov et al., 2012). The heterodimer takes an L-shape form on
the DR3 with a proper orientation of RXR on the upstream and
VDR on the downstream half site (similar to SAXS model). The
complex supports also the asymmetric open architecture from
SAXS data. Both LBDs are positioned above the 5′ upstream
half site as shown on Figure 9A. This result also emphasizes the
importance of the hinges for the correct function of the complex.
The main nature of the flexible hinge of RXR allows to contact the
CTE helix with helix 1 and makes it possible to adopt differential
spacing in DR REs. In addition, the coiled RXR hinge has to be
long to reach DBD to its LBD which is located on the opposite
side of the DR3VDRE. The cryo-EM data points to one inter-
esting feature, the potential in modulation of the DNA-binding
using the 17 aa long A/B domain of VDR, which in fact interacts
with the major groove of the DNA.
The H/D exchange (HDX) is a great tools to address the
dynamic properties of the RXR-VDR-SRC1 complex (Zhang
et al., 2011). The addition of RXR to VDR stabilizes region with
helices 6–7, very similar to what is seen when some of agonists
bind to VDR. As expected, upon 1,25D3 binding in the VDR
LBD the helices 1, 3, 5–7, and 11 (the actual region that forms
the LBP) have been stabilized, but binding efficiency of RXR to
VDR is not enhanced. For RXR the helices 7 and 10 are stabilized
(increase of the heterodimerisation) and an allosteric commu-
nication has been shown for the helix 3 of RXR. The 9-cis RA
binding in general stabilized RXR, but in contrast to the crystal
structure, it increased the fluctuation in helix 12. This observation
may also indicate that the crystal structure take the minimized
FIGURE 9 | The full length RXR-VDR structural model derived from
SAXS and cryo-EM experiments. (A) A surface representation of the
RXR(blue)-VDR(green) heterodimer is shown on DR3VDRE. The possible
location of the coactivator peptide (orange) is highlighted as well. The 5′-
and 3′-prime orientation of the DR3 is annotated. (B) Ribbon representation
of the same complex shows the relative organization and fold of LBD, DBD
and the connective hinge between them. The β-sheets are shown in yellow
color.
energy conformation of the complex, but in reality it is more
dynamic. The allosteric communication in VDR upon 9-cis RA
binding was seen in the helices 3, 5, and 7 that are adjacent from
the heterodimerisation interface pointing to modulation of the
complex upon only 9-cis RA binding. Surprisingly, the concur-
rent binding of 1,25D3 and 9-cis RA has a destabilizing affect
Frontiers in Physiology | Integrative Physiology June 2014 | Volume 5 | Article 191 | 18
Molnár Structural data for VDR
on the VDR DBD. A stronger increase of the VDR binding has
been observed compared to RXR DBD in the presence of cDR3
element and in the absence of ligands, pointing to the higher
contribution of the VDR for DNA interaction. In addition, inter-
esting allosteric stabilization were observed for the VDR hinge
and for helices 7–8 and 9–10. Moreover, unexpectedly the helix
12 of VDR showed increased fluctuation. However, it should be
noted that in this experimental setup a coactivator has been miss-
ing from the protein complex (see below). The binding to the
natural VDRE from CYP24A1 gene showed similar result except
it seemed that 5′-AGGTCA-3′ half-site was occupied by VDR and
helix 12 of RXR was more stable. Unexpectedly, the stability of
the heterodimer on CYP24A1 VDRE was reduced although the
binding affinities of the two VDREs are in the same magnitude.
The interaction of the coactivator SRC1, that contained three
LXXLL motifs, with the heterodimer bound to both 1,25D3 and
9-cis RA increased the stability of VDR’s helix 12 and helices 3
and 10–11 of RXR. Helices 3 and 4 of VDR cannot be further
stabilized since they achieve maximal stabilization upon 1,25D3
binding. For RXR the loop between helices 10 and 11 is important
in the formation of the hydrophobic groove facilitating coacti-
vator binding. Besides the classical charge clamp RXR contains
the so called “aromatic clamp” consisting of residues in helices
3 (F437, F277) and 12 (F450) that is important for coactivator
binding. As expected in the absence of both ligand no coactivator
interaction was observed and the separate addition of the 1,25D3
or 9-cis RA recruited the coactivator in a ligand-specific manner.
Further HDX and cell based experiments showed that a simulta-
neous binding of the coactivator to both receptors is important
and in the interaction with the RXR-VDR heterodimer only one
SRC1 molecule is required (Zhang et al., 2011). This is in con-
trast to the SAXS derived model (Rochel et al., 2011). For the
RXR-VDR-SRC1 complex the helix 12 of VDR has been stabi-
lized upon addition of the DNA. In addition, HDX shows that
the DNA-binding enhances the recruitment of SRC1 to RXR, thus
the binding of the DNA stabilizes the recruitment of SRC1 to the
whole heterodimer not just to the partner such as VDR.
Both, the SAXS and cryo-EM, studies highlighted the open
architecture conformation in solution unlike it has been shown
for the full length PPAR-RXR (Chandra et al., 2008). The recent
crystal structure of the full length RXRα–LXRβ on DR4 RE
provides also a support for the open conformation of the NR
heterodimer complex (Lou et al., 2014). It will have to be seen
whether the closed PPAR-RXR complex on DR1 is and excep-
tion, although more plausible is the open conformation giving a
rather high dynamic freedom for the NR heterodimer in the large
transcriptional complex.
CONCLUSIONS
The main aim of this review was to collect and discuss struc-
tural data that is related to vitamin D signaling. The structural
data for various isolated domains (LBD and DBD) show their
organization on atomic level. This data is sufficient for under-
standing the particular ligand- and DNA-protein interactions
but fails to provide spatial information on the mutual orienta-
tion of the domains of RXR-VDR on its natural promoters. It
also fails to highlight inter-domain communication after DNA-,
ligand- or cofactor-binding. However, they are irreplaceable tools
for structure-based drug design and mechanistic view of the
VDR action. The dissemination of the information derived from
structural data and in silico models may help to understand
how VDR works in its natural settings and provides a space for
the intervention in various diseases. The recent SAXS, Cryo-EM
and H/D exchange studies with full length RXR-VDR complexes
show more complex views on VDR function and provide first
tools for the integration of structural information with genomic,
epi-genomic, transcriptional and functional data.
FUTURE PERSPECTIVE
There are numerous scientific questions connected to VDR that
may be interesting to answer on structural level. The list is not
complete but here are some of them:
• Do the subtle differences between the various ligand-bound
VDR complexes indeed represent the differences in the biolog-
ical specificities and activities in vivo?
• Can the LBP related measurements and other descriptors be
related to the potency of VDR ligands?
• Are there some additional natural compounds that are able to
bind VDR and thus influence the metabolism and detoxifica-
tion?
• What is the real role of the insertion domain in VDR?
• Is it possible to relate structurally the binding affinities of the
RXR-VDR complexes with DNA?
• Are there other in vivo significant binding modes of VDR to the
DNA such as monomers?
• What is the architecture of the RXR-VDR complex on non-
DR3VDREs and in indirect DNA interactions?
• How the recruitment specificity of the LXXLL containing pro-
teins is regulated in the cell?
• How is the inter-domain communication precisely mediated
upon ligand- DNA- and protein-VDR interaction?
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